Literature DB >> 24121438

Structural basis for modulation of a G-protein-coupled receptor by allosteric drugs.

Ron O Dror1, Hillary F Green, Celine Valant, David W Borhani, James R Valcourt, Albert C Pan, Daniel H Arlow, Meritxell Canals, J Robert Lane, Raphaël Rahmani, Jonathan B Baell, Patrick M Sexton, Arthur Christopoulos, David E Shaw.   

Abstract

The design of G-protein-coupled receptor (GPCR) allosteric modulators, an active area of modern pharmaceutical research, has proved challenging because neither the binding modes nor the molecular mechanisms of such drugs are known. Here we determine binding sites, bound conformations and specific drug-receptor interactions for several allosteric modulators of the M2 muscarinic acetylcholine receptor (M2 receptor), a prototypical family A GPCR, using atomic-level simulations in which the modulators spontaneously associate with the receptor. Despite substantial structural diversity, all modulators form cation-π interactions with clusters of aromatic residues in the receptor extracellular vestibule, approximately 15 Å from the classical, 'orthosteric' ligand-binding site. We validate the observed modulator binding modes through radioligand binding experiments on receptor mutants designed, on the basis of our simulations, either to increase or to decrease modulator affinity. Simulations also revealed mechanisms that contribute to positive and negative allosteric modulation of classical ligand binding, including coupled conformational changes of the two binding sites and electrostatic interactions between ligands in these sites. These observations enabled the design of chemical modifications that substantially alter a modulator's allosteric effects. Our findings thus provide a structural basis for the rational design of allosteric modulators targeting muscarinic and possibly other GPCRs.

Mesh:

Substances:

Year:  2013        PMID: 24121438     DOI: 10.1038/nature12595

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  40 in total

1.  Electrostatics of nanosystems: application to microtubules and the ribosome.

Authors:  N A Baker; D Sept; S Joseph; M J Holst; J A McCammon
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-21       Impact factor: 11.205

2.  Application of a kinetic model to the apparently complex behavior of negative and positive allosteric modulators of muscarinic acetylcholine receptors.

Authors:  Vimesh Avlani; Lauren T May; Patrick M Sexton; Arthur Christopoulos
Journal:  J Pharmacol Exp Ther       Date:  2004-01-07       Impact factor: 4.030

Review 3.  Flexible ligand docking to multiple receptor conformations: a practical alternative.

Authors:  Maxim Totrov; Ruben Abagyan
Journal:  Curr Opin Struct Biol       Date:  2008-02-25       Impact factor: 6.809

4.  Site-directed mutagenesis reveals two epitopes involved in the subtype selectivity of the allosteric interactions of gallamine at muscarinic acetylcholine receptors.

Authors:  A L Gnagey; M Seidenberg; J Ellis
Journal:  Mol Pharmacol       Date:  1999-12       Impact factor: 4.436

Review 5.  Structure-based drug screening for G-protein-coupled receptors.

Authors:  Brian K Shoichet; Brian K Kobilka
Journal:  Trends Pharmacol Sci       Date:  2012-04-13       Impact factor: 14.819

6.  Critical amino acid residues of the common allosteric site on the M2 muscarinic acetylcholine receptor: more similarities than differences between the structurally divergent agents gallamine and bis(ammonio)alkane-type hexamethylene-bis-[dimethyl-(3-phthalimidopropyl)ammonium]dibromide.

Authors:  Xi-Ping Huang; Stefanie Prilla; Klaus Mohr; John Ellis
Journal:  Mol Pharmacol       Date:  2005-06-03       Impact factor: 4.436

7.  The tetrahydroisoquinoline derivative SB269,652 is an allosteric antagonist at dopamine D3 and D2 receptors.

Authors:  Elena Silvano; Mark J Millan; Clotilde Mannoury la Cour; Yang Han; Lihua Duan; Suzy A Griffin; Robert R Luedtke; Gabriella Aloisi; Mario Rossi; Francesca Zazzeroni; Jonathan A Javitch; Roberto Maggio
Journal:  Mol Pharmacol       Date:  2010-08-11       Impact factor: 4.436

Review 8.  Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders.

Authors:  P Jeffrey Conn; Carrie K Jones; Craig W Lindsley
Journal:  Trends Pharmacol Sci       Date:  2009-02-07       Impact factor: 14.819

9.  Structure and dynamics of the M3 muscarinic acetylcholine receptor.

Authors:  Andrew C Kruse; Jianxin Hu; Albert C Pan; Daniel H Arlow; Daniel M Rosenbaum; Erica Rosemond; Hillary F Green; Tong Liu; Pil Seok Chae; Ron O Dror; David E Shaw; William I Weis; Jürgen Wess; Brian K Kobilka
Journal:  Nature       Date:  2012-02-22       Impact factor: 49.962

10.  Crystal structure of the β2 adrenergic receptor-Gs protein complex.

Authors:  Søren G F Rasmussen; Brian T DeVree; Yaozhong Zou; Andrew C Kruse; Ka Young Chung; Tong Sun Kobilka; Foon Sun Thian; Pil Seok Chae; Els Pardon; Diane Calinski; Jesper M Mathiesen; Syed T A Shah; Joseph A Lyons; Martin Caffrey; Samuel H Gellman; Jan Steyaert; Georgios Skiniotis; William I Weis; Roger K Sunahara; Brian K Kobilka
Journal:  Nature       Date:  2011-07-19       Impact factor: 49.962

View more
  136 in total

1.  Structural Insight into Specificity of Interactions between Nonconventional Three-finger Weak Toxin from Naja kaouthia (WTX) and Muscarinic Acetylcholine Receptors.

Authors:  Ekaterina N Lyukmanova; Zakhar O Shenkarev; Mikhail A Shulepko; Alexander S Paramonov; Anton O Chugunov; Helena Janickova; Eva Dolejsi; Vladimir Dolezal; Yuri N Utkin; Victor I Tsetlin; Alexander S Arseniev; Roman G Efremov; Dmitry A Dolgikh; Mikhail P Kirpichnikov
Journal:  J Biol Chem       Date:  2015-08-04       Impact factor: 5.157

Review 2.  Protein Allostery and Conformational Dynamics.

Authors:  Jingjing Guo; Huan-Xiang Zhou
Journal:  Chem Rev       Date:  2016-02-15       Impact factor: 60.622

3.  Identification of G protein-biased agonists that fail to recruit β-arrestin or promote internalization of the D1 dopamine receptor.

Authors:  Jennie L Conroy; R Benjamin Free; David R Sibley
Journal:  ACS Chem Neurosci       Date:  2015-02-20       Impact factor: 4.418

4.  In silico study of the structurally similar ORL1 receptor agonist and antagonist pairs reveal possible mechanism of receptor activation.

Authors:  Milan Senćanski; Ljiljana Dosen-Mićović
Journal:  Protein J       Date:  2014-06       Impact factor: 2.371

Review 5.  Docking Screens for Novel Ligands Conferring New Biology.

Authors:  John J Irwin; Brian K Shoichet
Journal:  J Med Chem       Date:  2016-03-15       Impact factor: 7.446

6.  Investigating Small-Molecule Ligand Binding to G Protein-Coupled Receptors with Biased or Unbiased Molecular Dynamics Simulations.

Authors:  Kristen A Marino; Marta Filizola
Journal:  Methods Mol Biol       Date:  2018

7.  Differences in allosteric communication pipelines in the inactive and active states of a GPCR.

Authors:  Supriyo Bhattacharya; Nagarajan Vaidehi
Journal:  Biophys J       Date:  2014-07-15       Impact factor: 4.033

8.  Discovery and characterization of a G protein-biased agonist that inhibits β-arrestin recruitment to the D2 dopamine receptor.

Authors:  R Benjamin Free; Lani S Chun; Amy E Moritz; Brittney N Miller; Trevor B Doyle; Jennie L Conroy; Adrian Padron; Julie A Meade; Jingbo Xiao; Xin Hu; Andrés E Dulcey; Yang Han; Lihua Duan; Steve Titus; Melanie Bryant-Genevier; Elena Barnaeva; Marc Ferrer; Jonathan A Javitch; Thijs Beuming; Lei Shi; Noel T Southall; Juan J Marugan; David R Sibley
Journal:  Mol Pharmacol       Date:  2014-04-22       Impact factor: 4.436

9.  Estimation of ligand affinity constants for receptor states in functional studies involving the allosteric modulation of G protein-coupled receptors: implications for ligand bias.

Authors:  Frederick J Ehlert; Michael T Griffin
Journal:  J Pharmacol Toxicol Methods       Date:  2014-01-13       Impact factor: 1.950

10.  Multiscale design of coarse-grained elastic network-based potentials for the μ opioid receptor.

Authors:  Mathieu Fossépré; Laurence Leherte; Aatto Laaksonen; Daniel P Vercauteren
Journal:  J Mol Model       Date:  2016-08-26       Impact factor: 1.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.